Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Detailed Analysis of Current Migraine Treatment Trends by Treatment Groups in a Large Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases
Headache
P1 - Poster Session 1 (8:00 AM-9:00 AM)
12-003
With the emergence of calcitonin gene-related peptide (anti-CGRP) medications the migraine treatment landscape has evolved recently and a detailed review of a large subset of the US Migraine population may offer insight into current prescription trends.
We evaluated a large subset of the US Migraine population under various groups stratified by medication to analyze current migraine treatment trends.
Based on ICD-10 codes (Health Verity claims data; 8/2018-7/2021; N=187,780) Chronic vs. Other migraine groups were defined under the following:  anti-CGRP, non-specific migraine preventive treatment, migraine-specific acute treatment, non-specific acute treatment, and no treatment. Baseline and Follow-up periods defined as 12 months prior and after the index.

At baseline, Chronic Migraine group (N=21,879) were further subdivided into: non-specific migraine preventive treatment (41.2%), no treatment (17.6%), anti-CGRP (16.1%), migraine-specific acute (15.0%), and non-specific acute treatment (10.0%) groups.  Other Migraine group (N=165,901) were divided under following subgroups: non-specific migraine preventive treatment group (34.4%), no treatment (26.9%), migraine-specific acute (18.9%), non-specific acute treatment (15.4%), and anti-CGRP (4.4%) groups. 


The anti-CGRP treatment group had the highest percentage of all-cause Neurology visits among the 5 treatment groups in Chronic and Other Migraine types during Baseline and Follow-up periods. Acute Non-Specific treatment groups had the most frequent visits to the emergency department in both migraine types during Baseline and Follow-up.


Prescription trends from a large subset of the US Migraine population revealed significant differences among treatment groups. The recent introduction of novel calcitonin gene-related peptide (anti-CGRP) medications has transformed the migraine treatment landscape.
Authors/Disclosures
Alexander Kuka (Click Therapeutics)
PRESENTER
No disclosure on file
Olya Besedina (Click Therapeutics Inc.) No disclosure on file
Mariya Petrova (Click Therapeutics) No disclosure on file
Brendan Hare No disclosure on file
Alankar Gupta, MD (Click Therapeutics) Dr. Gupta has received personal compensation for serving as an employee of Click Therapeutics.
Shaheen E. Lakhan, MD, PhD, MEd, FAAN Dr. Lakhan has received personal compensation for serving as an employee of Zogenix, Fern Health, Thriveworks, The Learning Corp, Click Therapeutics. Dr. Lakhan has received personal compensation in the range of $1,000,000+ for serving as a Consultant for Shaheen Lakhan, MD, PhD, LLC. Dr. Lakhan has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine, Fern Health, Lin Health. Dr. Lakhan has received personal compensation in the range of $500,000-$999,999 for serving as an officer or member of the Board of Directors for Click Therapeutics, SpineThera. Dr. Lakhan has stock in Zogenix, NeuroSport, Click Therapeutics, SpineThera.